Abstract 1698P
Background
The quality of life of cancer patients, and its improvement, depend on many factors. Digital engagement tools enable rich real-world data collection and deep comparative analysis.
Methods
Patients report several aspects of their condition on the CareAcross interactive online platforms and receive personalised support to manage side-effects. Data from patients who reported side-effects at least twice were analysed for incidence (any report) and improvement (absence at the end of the observation period). Comparative analysis was conducted regarding metastatic status and relevant comorbidities.
Results
2174 patients reported side-effects at least twice: 1557 breast (BC), 402 lung (LC), 144 prostate (PC) and 71 colorectal (CC) cancer patients. 477 had metastatic disease; comorbidities included heart condition, hypertension, diabetes, and others. The analysis focused on the side-effects reported across all 4 cancer types: fatigue, sleep problems and dry mouth (reported by 31-73% across patient groups). Subgroup reporting, overall & final incidence, and incremental improvement (without vs with metastases; without vs with comorbidities) are shown in the table. Fatigue was more improved for non-metastatic patients. Dry mouth was better controlled for BC and LC patients without metastases and without comorbidities. Sleep was more improved for patients with comorbidities, except those with BC. Among BC patients, those without comorbidities saw greater improvements. On the contrary, PC patients with comorbidities improved more than those without. PC patients with metastases improved more than those with early disease, except for fatigue. LC patients without comorbidities experienced almost twice the improvement in fatigue, than those with comorbidities. Table: 1698P
| Metastatic status | Comorbidities | ||||||||||
| N | Y | N | Y | N vs Y | N | Y | N | Y | N vs Y | ||
| Incidence | Overall | Final | Incremental improvement vs Y | Overall | Final | Incremental improvement vs Y | |||||
| Breast | Fatigue | 70% | 70% | 37% | 45% | 30% | 66% | 73% | 36% | 40% | 2% |
| Sleep | 53% | 55% | 28% | 25% | -12% | 53% | 54% | 26% | 29% | 7% | |
| Dry mouth | 36% | 37% | 12% | 14% | 9% | 31% | 41% | 9% | 15% | 14% | |
| Lung | Fatigue | 70% | 76% | 47% | 54% | 15% | 69% | 76% | 39% | 60% | 101% |
| Sleep | 43% | 41% | 16% | 17% | 5% | 38% | 45% | 16% | 17% | -7% | |
| Dry mouth | 41% | 40% | 15% | 19% | 19% | 34% | 46% | 13% | 21% | 13% | |
| Prostate | Fatigue | 63% | 70% | 31% | 38% | 11% | 70% | 60% | 36% | 30% | -4% |
| Sleep | 41% | 53% | 21% | 21% | -20% | 44% | 46% | 22% | 19% | -14% | |
| Dry mouth | 34% | 25% | 12% | 8% | -7% | 31% | 30% | 12% | 9% | -11% | |
| Colorectal | Fatigue | 60% | 61% | 26% | 36% | 40% | 48% | 71% | 24% | 34% | -4% |
| Sleep | 30% | 43% | 16% | 25% | 11% | 42% | 29% | 24% | 16% | -6% | |
| Dry mouth | 37% | 39% | 19% | 18% | -8% | 21% | 53% | 9% | 26% | 14% |
Conclusions
The increased availability and granularity of data, can help reveal unmet needs and possible optimisation patterns through deep analyses, improving the potential to offer personalised care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Care Across Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.